Skip Navigation Bar
 

Unified Medical Language System® (UMLS®)

2012AB MedDRA Source Information

Counts

 (skip to: notes  samples)

Attribute Name Description Count (MRSAT.RRF)
SMQ_TERM_ADDVERSION Standardised MedDRA Query (SMQ) Addition Version. Version of MedDRA in which term was added to the SMQ. 118064
SMQ_TERM_CAT Standardised MedDRA Query (SMQ) Term Category. A single alphabetical letter indicating the category of the term for application of the SMQ algorithm. If the SMQ does not use algorithms, then all Term_category values are assigned "A." For a child SMQ, this field is assigned "S." 118064
SMQ_TERM_LMVERSION Standardised MedDRA Query (SMQ) Last Modified Version. Version of MedDRA in which term was last modified in the SMQ. 118064
SMQ_TERM_SCOPE Standardised MedDRA Query (SMQ) Term Scope. Defines the MedDRA term as a member of the broad scope (1), narrow scope (2) of the SMQ search, or a child SMQ (0) (zero). 118064
SMQ_TERM_STATUS Standardised MedDRA Query (SMQ) Term Status. Identifies a term as active ("A") or inactive ("I") within this SMQ. 118064
SMQ_TERM_WEIGHT Standardised MedDRA Query (SMQ) Term Weight. Used for some SMQ algorithms; "0" is used as default. 118064
SMQ_TERM_LEVEL Standardised MedDRA Query (SMQ) Term Level. The MedDRA hierarchy level of a term (4=PT, 5=LLT) or 0 (zero) for a child SMQ. 39019
MPS MedDRA primary SOC (PTs may have multiple treepositions, but each has a primary soc) 19550
SMQ_ALGO Standardised MedDRA Query (SMQ) Algorithm. Boolean expression of algorithm for the SMQ. "N" if the SMQ does not utilize an algorithm. 203
SMQ_LEVEL Standardised MedDRA Query (SMQ) Level. Value between 1 and 5 identifying the level of the SMQ within the hierarchy of SMQs; 1 is the most general, 5 is the most narrow. 203
SMQ_STATUS Standardised MedDRA Query (SMQ) Status. "A" = active; "I" = inactive. 203
SMQ_SOURCE Standardised MedDRA Query (SMQ) Source. Source for the development of the SMQ, e.g. medical references. 163
SOS Scope Statement 106
MISO MedDRA Serial Code International SOC Sort Order Digit (01-26) 26

Notes

  • Attributes included every discrete piece of information about a concept, an atom, or a relationship that is not part of the basic Metathesaurus concept structure or distributed in one of the relationship files.
  • Attribute Names (ATN) are based on source documentation or NLMs understanding of the source.
  • Sample attribute values (ATV) are provided for each ATN in the source.
  • Sample data highlight examples of ATNs and Attribute Values (ATV) in MRSAT.RRF.
  • See Metathesaurus Documentation for a complete list of attribute names.
  • See Section 2.5 of the UMLS Reference Manual for more information on attributes in the UMLS Metathesaurus.

Sample Data

SMQ_TERM_ADDVERSION

  (return to top)
CUI METAUI STYPE ATN ATV STR
C1869008 R92105430 RUI SMQ_TERM_ADDVERSION 8.0 Acute renal failure (SMQ)
C1444565 R92095369 RUI SMQ_TERM_ADDVERSION 10.0 Cardiopulmonary failure
C1869023 R92107183 RUI SMQ_TERM_ADDVERSION 10.0 Haemolytic disorders (SMQ)
C0011609 R92069189 RUI SMQ_TERM_ADDVERSION 8.0 Drug eruption NOS
C0235342 R92080742 RUI SMQ_TERM_ADDVERSION 8.1 Necrosis mouth
C0038218 R92102949 RUI SMQ_TERM_ADDVERSION 8.1 Asthmatic crisis
C0018378 R92072990 RUI SMQ_TERM_ADDVERSION 8.1 Guillain Barre syndrome
C0027868 R92081107 RUI SMQ_TERM_ADDVERSION 8.1 Neuromyopathy
C0156006 R92065648 RUI SMQ_TERM_ADDVERSION 9.0 Chronic or unspecified duodenal ulcer with hemorrhage, with obstruction
C0549453 R92073061 RUI SMQ_TERM_ADDVERSION 9.0 Haematoma traumatic
C0263836 R92073527 RUI SMQ_TERM_ADDVERSION 9.0 Hemarthrosis involving upper arm
C1869102 R92112282 RUI SMQ_TERM_ADDVERSION 9.0 Haemorrhage terms (excl laboratory terms) (SMQ)
C0151693 R92098118 RUI SMQ_TERM_ADDVERSION 9.0 Haemorrhage adrenal
C0220887 R92098227 RUI SMQ_TERM_ADDVERSION 9.0 Other immediate postpartum haemorrhage, postpartum
C0683357 R92070587 RUI SMQ_TERM_ADDVERSION 9.0 Excessive drinking
C0151576 R92067605 RUI SMQ_TERM_ADDVERSION 9.0 CPK increased
C1869046 R92114318 RUI SMQ_TERM_ADDVERSION 9.0 Neuroleptic malignant syndrome (SMQ)
C0004245 R92062220 RUI SMQ_TERM_ADDVERSION 9.1 Atrioventricular block NOS
C0038525 R92073766 RUI SMQ_TERM_ADDVERSION 9.1 Hemorrhage subarachnoid

SMQ_TERM_CAT

  (return to top)
CUI METAUI STYPE ATN ATV STR
C0877723 R92081283 RUI SMQ_TERM_CAT A Nonallopathic lesions of cervical region, not elsewhere classified
C1963962 R92104487 RUI SMQ_TERM_CAT A Direct bilirubin abnormal
C0151798 R92077313 RUI SMQ_TERM_CAT A Liver necrosis
C1869020 R92106823 RUI SMQ_TERM_CAT A Liver infections (SMQ)
C1141915 R92099501 RUI SMQ_TERM_CAT A Hepatitis E antibody abnormal
C0857104 R92071494 RUI SMQ_TERM_CAT A Florid follicular conjunctivitis
C0236071 R92067229 RUI SMQ_TERM_CAT B Constriction throat
C0235551 R92069685 RUI SMQ_TERM_CAT B Edema laryngotracheal
C1869038 R92107752 RUI SMQ_TERM_CAT C Anaphylactic reaction (SMQ)
C1869026 R92108672 RUI SMQ_TERM_CAT A Agranulocytosis (SMQ)
C0522035 R92069661 RUI SMQ_TERM_CAT A Edema arms
C1869027 R92109027 RUI SMQ_TERM_CAT A Angioedema (SMQ)
C0575081 R92059836 RUI SMQ_TERM_CAT A Abnormality of gait
C0031117 R92081119 RUI SMQ_TERM_CAT A Neuropathy peripheral
C0014591 R92073716 RUI SMQ_TERM_CAT A Hemorrhage nasal
C0340775 R92093103 RUI SMQ_TERM_CAT A Vein, ruptured varicose
C1869046 R92114533 RUI SMQ_TERM_CAT D Neuroleptic malignant syndrome (SMQ)
C0155658 R92060403 RUI SMQ_TERM_CAT A Acute myocardial infarction, subendocardial infarction, subsequent episode of care
C1869050 R92115439 RUI SMQ_TERM_CAT C Anticholinergic syndrome (SMQ)

SMQ_TERM_LMVERSION

  (return to top)
CUI METAUI STYPE ATN ATV STR
C1869023 R92107145 RUI SMQ_TERM_LMVERSION 8.0 Haemolytic disorders (SMQ)
C1869024 R92107365 RUI SMQ_TERM_LMVERSION 8.0 Severe cutaneous adverse reactions (SMQ)
C1112611 R92099127 RUI SMQ_TERM_LMVERSION 8.1 Oropharyngitis
C1869027 R92109079 RUI SMQ_TERM_LMVERSION 8.1 Angioedema (SMQ)
C0877638 R92093962 RUI SMQ_TERM_LMVERSION 8.1 Wheezing aggravated
C1869029 R92109662 RUI SMQ_TERM_LMVERSION 8.1 Dyslipidaemia (SMQ)
C0002886 R92061269 RUI SMQ_TERM_LMVERSION 8.1 Anaemia macrocytic
C1869037 R92110536 RUI SMQ_TERM_LMVERSION 8.1 Peripheral neuropathy (SMQ)
C1869102 R92111226 RUI SMQ_TERM_LMVERSION 12.0 Haemorrhage terms (excl laboratory terms) (SMQ)
C1869102 R92112496 RUI SMQ_TERM_LMVERSION 12.0 Haemorrhage terms (excl laboratory terms) (SMQ)
C1869043 R92113649 RUI SMQ_TERM_LMVERSION 9.0 Hyperglycaemia/new onset diabetes mellitus (SMQ)
C0241442 R92086515 RUI SMQ_TERM_LMVERSION 11.1 Protrusion tongue
C1869047 R92114693 RUI SMQ_TERM_LMVERSION 9.0 Systemic lupus erythematosus (SMQ)
C0856480 R92066774 RUI SMQ_TERM_LMVERSION 9.1 Confusional state (organic, acute or subacute)
C1869050 R92115641 RUI SMQ_TERM_LMVERSION 9.1 Anticholinergic syndrome (SMQ)
C1869062 R92117486 RUI SMQ_TERM_LMVERSION 9.1 Retroperitoneal fibrosis (SMQ)
C1869062 R92117489 RUI SMQ_TERM_LMVERSION 9.1 Retroperitoneal fibrosis (SMQ)
C1869070 R92118732 RUI SMQ_TERM_LMVERSION 10.0 Dementia (SMQ)
C2363826 R103656373 RUI SMQ_TERM_LMVERSION 11.1 SI QIII TIII pattern

SMQ_TERM_SCOPE

  (return to top)
CUI METAUI STYPE ATN ATV STR
C1869007 R92105055 RUI SMQ_TERM_SCOPE 1 Rhabdomyolysis/myopathy (SMQ)
C0877560 R92097009 RUI SMQ_TERM_SCOPE 1 Edema due to renal disease
C1869024 R92107445 RUI SMQ_TERM_SCOPE 2 Severe cutaneous adverse reactions (SMQ)
C1112608 R92099121 RUI SMQ_TERM_SCOPE 2 Hypocytosis
C0522035 R92069754 RUI SMQ_TERM_SCOPE 1 Edema upper limb
C0002994 R92098294 RUI SMQ_TERM_SCOPE 2 Oedema angioneurotic
C1869027 R92109339 RUI SMQ_TERM_SCOPE 1 Angioedema (SMQ)
C1536916 R92065409 RUI SMQ_TERM_SCOPE 2 Cholesterol depletion
C1869029 R92109745 RUI SMQ_TERM_SCOPE 2 Dyslipidaemia (SMQ)
C0018378 R92072992 RUI SMQ_TERM_SCOPE 2 Guillain-Barre syndrome
C1869039 R92110873 RUI SMQ_TERM_SCOPE 2 Depression and suicide/self-injury (SMQ)
C1869040 R92111196 RUI SMQ_TERM_SCOPE 2 Suicide/self-injury (SMQ)
C0391922 R92070094 RUI SMQ_TERM_SCOPE 2 Enteritis hemorrhagic
C0155789 R92081831 RUI SMQ_TERM_SCOPE 2 Oesophageal varices with bleeding
C1504419 R92102463 RUI SMQ_TERM_SCOPE 2 Pelvic hemorrhage
C0553732 R92086496 RUI SMQ_TERM_SCOPE 1 Prothrombin level decreased
C1869043 R92113412 RUI SMQ_TERM_SCOPE 1 Hyperglycaemia/new onset diabetes mellitus (SMQ)
C1869044 R92113742 RUI SMQ_TERM_SCOPE 2 Interstitial lung disease (SMQ)
C1735908 R92104237 RUI SMQ_TERM_SCOPE 2 Myocardial ischemia recurrent

SMQ_TERM_STATUS

  (return to top)
CUI METAUI STYPE ATN ATV STR
C1869007 R92105135 RUI SMQ_TERM_STATUS A Rhabdomyolysis/myopathy (SMQ)
C0019004 R92073079 RUI SMQ_TERM_STATUS A Haemodialysed
C0034063 R92069697 RUI SMQ_TERM_STATUS A Edema lung
C0235996 R92087047 RUI SMQ_TERM_STATUS A Raised liver enzymes
C1869017 R92106575 RUI SMQ_TERM_STATUS A Hepatic failure, fibrosis and cirrhosis and other liver damage-related conditions (SMQ)
C1869027 R92108798 RUI SMQ_TERM_STATUS A Angioedema (SMQ)
C1869027 R92109244 RUI SMQ_TERM_STATUS A Angioedema (SMQ)
C1869028 R92109497 RUI SMQ_TERM_STATUS A Asthma/bronchospasm (SMQ)
C0857322 R92061285 RUI SMQ_TERM_STATUS A Anaemic
C1168156 R92100183 RUI SMQ_TERM_STATUS A Segmented neutrophil percentage decreased
C1869102 R92111515 RUI SMQ_TERM_STATUS A Haemorrhage terms (excl laboratory terms) (SMQ)
C1869102 R92111603 RUI SMQ_TERM_STATUS A Haemorrhage terms (excl laboratory terms) (SMQ)
C1869102 R92111785 RUI SMQ_TERM_STATUS A Haemorrhage terms (excl laboratory terms) (SMQ)
C0024050 R92095685 RUI SMQ_TERM_STATUS A Lower gastrointestinal hemorrhage
C0149745 R92080077 RUI SMQ_TERM_STATUS A Mouth ulcer
C1869048 R92115203 RUI SMQ_TERM_STATUS A Taste and smell disorders (SMQ)
C1869050 R92115821 RUI SMQ_TERM_STATUS A Anticholinergic syndrome (SMQ)
C2609416 R92116239 RUI SMQ_TERM_STATUS A Arrhythmia related investigations, signs and symptoms (SMQ)
C0085621 R92084173 RUI SMQ_TERM_STATUS I Paralysis spastic

SMQ_TERM_WEIGHT

  (return to top)
CUI METAUI STYPE ATN ATV STR
C1869006 R92104871 RUI SMQ_TERM_WEIGHT 0 Torsade de pointes/QT prolongation (SMQ)
C0235851 R92100749 RUI SMQ_TERM_WEIGHT 0 Hyperbilirubinemia aggravated
C1869017 R92106474 RUI SMQ_TERM_WEIGHT 0 Hepatic failure, fibrosis and cirrhosis and other liver damage-related conditions (SMQ)
C1869017 R92106623 RUI SMQ_TERM_WEIGHT 0 Hepatic failure, fibrosis and cirrhosis and other liver damage-related conditions (SMQ)
C1869020 R92106871 RUI SMQ_TERM_WEIGHT 0 Liver infections (SMQ)
C1869023 R92107057 RUI SMQ_TERM_WEIGHT 0 Haemolytic disorders (SMQ)
C1112208 R92098766 RUI SMQ_TERM_WEIGHT 0 Septic phlebitis
C0600260 R92077641 RUI SMQ_TERM_WEIGHT 0 Lung disease obstructive
C1141929 R92099535 RUI SMQ_TERM_WEIGHT 0 Gastrointestinal oedema
C1869028 R92109484 RUI SMQ_TERM_WEIGHT 0 Asthma/bronchospasm (SMQ)
C1869029 R92109532 RUI SMQ_TERM_WEIGHT 0 Dyslipidaemia (SMQ)
C1869037 R92110344 RUI SMQ_TERM_WEIGHT 0 Peripheral neuropathy (SMQ)
C1869102 R92112190 RUI SMQ_TERM_WEIGHT 0 Haemorrhage terms (excl laboratory terms) (SMQ)
C1869102 R92112211 RUI SMQ_TERM_WEIGHT 0 Haemorrhage terms (excl laboratory terms) (SMQ)
C1869047 R92115131 RUI SMQ_TERM_WEIGHT 3 Systemic lupus erythematosus (SMQ)
C1869050 R92115649 RUI SMQ_TERM_WEIGHT 0 Anticholinergic syndrome (SMQ)
C1869062 R92117581 RUI SMQ_TERM_WEIGHT 0 Retroperitoneal fibrosis (SMQ)
C0042510 R92093171 RUI SMQ_TERM_WEIGHT 0 Ventricular fibrillation paroxysm
C1328585 R92102276 RUI SMQ_TERM_WEIGHT 0 Propofol syndrome

SMQ_TERM_LEVEL

  (return to top)
CUI METAUI LUI SUI STYPE CODE ATN ATV STR
C0472686 A10925505 L0797076 S0847563 CODE 10066348 SMQ_TERM_LEVEL 5 Continuous hemodiafiltration
C0019158 A2849382 L0019158 S0047899 CODE 10019717 SMQ_TERM_LEVEL 4 Hepatitis
C0852988 A1584966 L1372261 S1626355 CODE 10005820 SMQ_TERM_LEVEL 4 Blood thrombin decreased
C0019159 A1601768 L0019190 S1640906 CODE 10019782 SMQ_TERM_LEVEL 5 Hepatitis infectious NOS
C0438716 A0671443 L0291038 S0616413 CODE 10008486 SMQ_TERM_LEVEL 5 Chest pressure
C0857192 A2851146 L1382417 S1643745 CODE 10037893 SMQ_TERM_LEVEL 5 Rash trunk & limbs
C0239212 A2016887 L0298415 S2162859 CODE 10052440 SMQ_TERM_LEVEL 5 Erythema ear
C0031157 A1575592 L0031157 S1618537 CODE 10034688 SMQ_TERM_LEVEL 5 Peritonsillar abscess NOS
C0857337 A1586914 L1373410 S1628026 CODE 10006788 SMQ_TERM_LEVEL 5 Burning sensation in joints
C0234221 A4363255 L0277697 S0354253 CODE 10062860 SMQ_TERM_LEVEL 5 Acroparesthesia
C0006870 A1587973 L0006870 S1628930 CODE 10012341 SMQ_TERM_LEVEL 5 Dependence on cannabis
C0155967 A0949729 L0182838 S0891525 CODE 10017838 SMQ_TERM_LEVEL 5 Gastric ulcer, acute with haemorrhage
C0333549 A7161353 L1380767 S1640428 CODE 10019013 SMQ_TERM_LEVEL 4 Haemorrhagic infarction
C0020581 A13074484 L0280795 S1622235 CODE 10019528 SMQ_TERM_LEVEL 5 Hemorrhage ant chamber eye
C0153174 A0268320 L0180007 S0244529 CODE 10042923 SMQ_TERM_LEVEL 5 Syphilitic ruptured cerebral aneurysm
C0042134 A1115052 L0042134 S1057043 CODE 10046788 SMQ_TERM_LEVEL 4 Uterine haemorrhage
C0018924 A2601577 L0286278 S2939622 CODE 10059609 SMQ_TERM_LEVEL 5 Joint bleeding
C0151502 A1580289 L0161380 S1622462 CODE 10021653 SMQ_TERM_LEVEL 5 Increased anticoagulant effect
C1994994 A0411260 L0300129 S0370873 CODE 10015608 SMQ_TERM_LEVEL 5 Excessive thirst

MPS

  (return to top)
CUI METAUI LUI SUI STYPE CODE ATN ATV STR
C0154206 A1577141 L1368072 S1619851 SDUI 10001371 MPS 10014698 Adrenal medulla hyperfunction
C0004509 A0028374 L0004509 S0017219 SDUI 10003883 MPS 10038604 Azoospermia
C0855094 A1582247 L1370819 S1624108 SDUI 10003907 MPS 10029104 B-cell lymphoma stage IV
C0854279 A1582832 L1371195 S1624593 SDUI 10004153 MPS 10029205 Basal ganglion degeneration
C0854066 A1573721 L1366374 S1617103 SDUI 10004877 MPS 10022891 Biopsy spinal cord abnormal
C0853427 A1583876 L1371742 S1625486 SDUI 10004881 MPS 10022891 Biopsy stomach normal
C0855627 A1583521 L1371584 S1625222 SDUI 10005371 MPS 10022891 Blood bilirubin unconjugated normal
C0392003 A1586264 L0758428 S1627425 SDUI 10006217 MPS 10021881 Breast cellulitis
C0006262 A0661140 L0006262 S0605259 SDUI 10006437 MPS 10038738 Bronchial fistula
C0521544 A0893227 L0723272 S0834805 SDUI 10008023 MPS 10029205 Cerebellar artery thrombosis
C0549545 A2850541 L1030705 S1617439 SDUI 10009669 MPS 10022891 Clot retraction abnormal
C0009417 A0041143 L0009417 S0026645 SDUI 10010069 MPS 10022891 Colposcopy
C0011609 A7160665 L0013174 S0004902 SDUI 10013687 MPS 10040785 Drug eruption
C0266328 A0550449 L0390659 S0483237 SDUI 10014172 MPS 10010331 Ectopic ureter
C0553891 A1598602 L1379427 S1638208 SDUI 10015894 MPS 10042613 Extubation
C0855235 A1599079 L1379615 S1638617 SDUI 10016374 MPS 10037175 Feelings of worthlessness
C0221829 A1592162 L0292802 S1632601 SDUI 10016387 MPS 10042613 Female condom
C0744032 A1599330 L1379721 S1638831 SDUI 10016687 MPS 10042613 Finger repair operation
C0852925 A1600370 L1380190 S1639673 SDUI 10017982 MPS 10017947 Gastrointestinal necrosis

SMQ_ALGO

  (return to top)
CUI METAUI LUI SUI STYPE CODE ATN ATV STR
C1869006 A12057156 L6511616 S7585752 SDUI 20000001 SMQ_ALGO N Torsade de pointes/QT prolongation (SMQ)
C1869008 A12056800 L6511448 S7585289 SDUI 20000003 SMQ_ALGO N Acute renal failure (SMQ)
C1869009 A12057733 L6511462 S7585426 SDUI 20000005 SMQ_ALGO N Hepatic disorders (SMQ)
C1869013 A12056802 L6511443 S7585261 SDUI 20000009 SMQ_ALGO N Cholestasis and jaundice of hepatic origin (SMQ)
C1869015 A12056621 L6511665 S7585509 SDUI 20000011 SMQ_ALGO N Liver neoplasms, malignant and unspecified (SMQ)
C1869017 A12057343 L6511463 S7585427 SDUI 20000013 SMQ_ALGO N Hepatic failure, fibrosis and cirrhosis and other liver damage-related conditions (SMQ)
C1869018 A12057698 L6511446 S7585282 SDUI 20000014 SMQ_ALGO N Congenital, familial, neonatal and genetic disorders of the liver (SMQ)
C1869024 A12057520 L6511492 S7585682 SDUI 20000020 SMQ_ALGO N Severe cutaneous adverse reactions (SMQ)
C1869038 A12057161 L6511588 S7585462 SDUI 20000021 SMQ_ALGO A or (B and C) or (D and (B or C)) Anaphylactic reaction (SMQ)
C1869025 A12057005 L6511764 S7585273 SDUI 20000022 SMQ_ALGO A or (B and C) Acute pancreatitis (SMQ)
C1869039 A12057871 L6511451 S7585311 SDUI 20000035 SMQ_ALGO N Depression and suicide/self-injury (SMQ)
C1869040 A12057699 L6511910 S7585713 SDUI 20000037 SMQ_ALGO N Suicide/self-injury (SMQ)
C1869102 A12057522 L6511581 S7585409 SDUI 20000039 SMQ_ALGO N Haemorrhage terms (excl laboratory terms) (SMQ)
C1869044 A12057523 L6511722 S7585477 SDUI 20000042 SMQ_ALGO N Interstitial lung disease (SMQ)
C1869048 A12057163 L6511854 S7585728 SDUI 20000046 SMQ_ALGO N Taste and smell disorders (SMQ)
C1869050 A12057347 L6511537 S7585552 SDUI 20000048 SMQ_ALGO A or (B and C and D) Anticholinergic syndrome (SMQ)
C1869100 A12056985 L6511495 S7585725 SDUI 20000054 SMQ_ALGO N Tachyarrhythmias (incl supraventricular and ventricular tachyarrhythmias) (SMQ)
C1869058 A12057872 L6511566 S7585252 SDUI 20000060 SMQ_ALGO N Cerebrovascular disorders (SMQ)
C1869060 A12057703 L6511830 S7585484 SDUI 20000063 SMQ_ALGO N Ischaemic cerebrovascular conditions (SMQ)

SMQ_LEVEL

  (return to top)
CUI METAUI LUI SUI STYPE CODE ATN ATV STR
C1869009 A12057733 L6511462 S7585426 SDUI 20000005 SMQ_LEVEL 1 Hepatic disorders (SMQ)
C1869012 A12057868 L6511726 S7585510 SDUI 20000008 SMQ_LEVEL 3 Liver related investigations, signs and symptoms (SMQ)
C1869013 A12056802 L6511443 S7585261 SDUI 20000009 SMQ_LEVEL 3 Cholestasis and jaundice of hepatic origin (SMQ)
C1869014 A12057518 L6511652 S7585428 SDUI 20000010 SMQ_LEVEL 4 Hepatitis, non-infectious (SMQ)
C1869018 A12057698 L6511446 S7585282 SDUI 20000014 SMQ_LEVEL 2 Congenital, familial, neonatal and genetic disorders of the liver (SMQ)
C1869020 A12057519 L6511530 S7585506 SDUI 20000016 SMQ_LEVEL 2 Liver infections (SMQ)
C1869038 A12057161 L6511588 S7585462 SDUI 20000021 SMQ_LEVEL 1 Anaphylactic reaction (SMQ)
C1869027 A12056622 L6511474 S7585499 SDUI 20000024 SMQ_LEVEL 1 Angioedema (SMQ)
C1869029 A12056804 L6511636 S7585322 SDUI 20000026 SMQ_LEVEL 1 Dyslipidaemia (SMQ)
C1869035 A12057345 L6511725 S7585492 SDUI 20000032 SMQ_LEVEL 1 Lack of efficacy/effect (SMQ)
C1869037 A12057160 L6511794 S7585607 SDUI 20000034 SMQ_LEVEL 1 Peripheral neuropathy (SMQ)
C1869039 A12057871 L6511451 S7585311 SDUI 20000035 SMQ_LEVEL 1 Depression and suicide/self-injury (SMQ)
C1869102 A12057522 L6511581 S7585409 SDUI 20000039 SMQ_LEVEL 2 Haemorrhage terms (excl laboratory terms) (SMQ)
C1869042 A12057700 L6511649 S7585408 SDUI 20000040 SMQ_LEVEL 2 Haemorrhage laboratory terms (SMQ)
C1869043 A12057346 L6511583 S7585435 SDUI 20000041 SMQ_LEVEL 1 Hyperglycaemia/new onset diabetes mellitus (SMQ)
C1869045 A12057162 L6511592 S7585485 SDUI 20000043 SMQ_LEVEL 1 Ischaemic heart disease (SMQ)
C1869046 A12057701 L6511894 S7585566 SDUI 20000044 SMQ_LEVEL 1 Neuroleptic malignant syndrome (SMQ)
C1869049 A12056984 L6511672 S7585557 SDUI 20000047 SMQ_LEVEL 2 Myocardial infarction (SMQ)
C1869050 A12057347 L6511537 S7585552 SDUI 20000048 SMQ_LEVEL 1 Anticholinergic syndrome (SMQ)

SMQ_STATUS

  (return to top)
CUI METAUI LUI SUI STYPE CODE ATN ATV STR
C1869006 A12057156 L6511616 S7585752 SDUI 20000001 SMQ_STATUS A Torsade de pointes/QT prolongation (SMQ)
C1869008 A12056800 L6511448 S7585289 SDUI 20000003 SMQ_STATUS A Acute renal failure (SMQ)
C1869091 A12057875 L6511505 S7585241 SDUI 20000004 SMQ_STATUS A Cardiac failure (SMQ)
C1869009 A12057733 L6511462 S7585426 SDUI 20000005 SMQ_STATUS A Hepatic disorders (SMQ)
C1869012 A12057868 L6511726 S7585510 SDUI 20000008 SMQ_STATUS A Liver related investigations, signs and symptoms (SMQ)
C1869013 A12056802 L6511443 S7585261 SDUI 20000009 SMQ_STATUS A Cholestasis and jaundice of hepatic origin (SMQ)
C1869014 A12057518 L6511652 S7585428 SDUI 20000010 SMQ_STATUS A Hepatitis, non-infectious (SMQ)
C1869015 A12056621 L6511665 S7585509 SDUI 20000011 SMQ_STATUS A Liver neoplasms, malignant and unspecified (SMQ)
C1869018 A12057698 L6511446 S7585282 SDUI 20000014 SMQ_STATUS A Congenital, familial, neonatal and genetic disorders of the liver (SMQ)
C1869020 A12057519 L6511530 S7585506 SDUI 20000016 SMQ_STATUS A Liver infections (SMQ)
C1869022 A12057158 L6511902 S7585629 SDUI 20000018 SMQ_STATUS A Pregnancy-related hepatic disorders (SMQ)
C1869024 A12057520 L6511492 S7585682 SDUI 20000020 SMQ_STATUS A Severe cutaneous adverse reactions (SMQ)
C1869038 A12057161 L6511588 S7585462 SDUI 20000021 SMQ_STATUS A Anaphylactic reaction (SMQ)
C1869026 A12056983 L6511876 S7585355 SDUI 20000023 SMQ_STATUS A Agranulocytosis (SMQ)
C1869029 A12056804 L6511636 S7585322 SDUI 20000026 SMQ_STATUS A Dyslipidaemia (SMQ)
C1869030 A12057521 L6511580 S7585405 SDUI 20000027 SMQ_STATUS A Haematopoietic cytopenias (SMQ)
C1869035 A12057345 L6511725 S7585492 SDUI 20000032 SMQ_STATUS A Lack of efficacy/effect (SMQ)
C1869039 A12057871 L6511451 S7585311 SDUI 20000035 SMQ_STATUS A Depression and suicide/self-injury (SMQ)
C1869040 A12057699 L6511910 S7585713 SDUI 20000037 SMQ_STATUS A Suicide/self-injury (SMQ)

SMQ_SOURCE

  (return to top)
CUI METAUI LUI SUI STYPE CODE ATN ATV STR
C1869007 A12057867 L6511681 S7585665 SDUI 20000002 SMQ_SOURCE Basic requirements for the use of terms for reporting adverse drug reactions (IV). Pharmacoepidemiology and Drug Safety 1993; 2:149-153. Myopathy. Reporting Adverse Drug Reactions: Definitions of Terms and Criteria for Their Use. Bankowski Z, Bruppacher R, Crusius I et al (Eds). Council for International Organizations of Medical Sciences: Geneva, 1999, pg. 16-17. Poels PJE and Gabreels FJM. Rhabdomyolysis: a review of the literature. Clin Neurol Neurosurg 1993; 95:175-192. Omar MA, Wilson JP, and Cox, TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Annals Pharmacother 2001; 35:1096-1107. Prendergast BD and George CF. Drug-induced rhabdomyolysis - mechanisms and management. Postgrad Med J 1993; 69:333-336. Rhabdomyolysis/myopathy (SMQ)
C1869038 A12057161 L6511588 S7585462 SDUI 20000021 SMQ_SOURCE 1 The Merck Manual. 15th edition. Merck, Sharp & Dohme Research Laboratories. (1987): 306-7 Anaphylactic reaction (SMQ)
C1869025 A12057005 L6511764 S7585273 SDUI 20000022 SMQ_SOURCE 1. Anonymous. Pancreatitis. Reporting Adverse Drug Reactions: Definitions of Terms and Criteria for Their Use. Bankowski Z, Bruppacher R, Crusius I et al (Eds). Council for International Organizations of Medical Sciences: Geneva, 1999, pp 53-54 2. Berardi RR and Montgomery PA. Pancreatitis. Pharmacotherapy: A Pathophysiologic Approach (5th Ed). DiPiro JT, Talbert RL, Yee GC et al (Eds). McGraw-Hill: New York, NY. 1999. pp 701-715 3. Greenberger NJ, Toskes PP, and Isselbacher KJ. Acute and chronic pancreatitis. Harrison's Principles of Internal Medicine (14th Ed). Fauci AS, Braunwald E, Isselbacher KJ et al (Eds). McGraw-Hill: New York, NY. 1998. pp 1741-1752 Acute pancreatitis (SMQ)
C1869028 A12057870 L6511607 S7585649 SDUI 20000025 SMQ_SOURCE 1. CIOMS publication, "Reporting Adverse Drug Reactions: Definitions of Terms and Criteria for their Use", pp 89 - 90, 1999.2. The Merck Manual, Seventeenth Edition, pp 556 - 568, 1999. 3. "Harrison's Principles of Internal Medicine", 14th edition, pp 1419 - 1426, 1998. Asthma/bronchospasm (SMQ)
C1869029 A12056804 L6511636 S7585322 SDUI 20000026 SMQ_SOURCE 1. Harrison's Principles of Internal Medicine, 16th Edition 2. Ross R: Atherosclerosis - an in?ammatory disease. N Engl J Med340:115-126,1999. 3. Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults Adult Treatment Panel III)Third Report of the National Cholesterol Education Program (NCEP) NIH - U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES - NIH Publication No.02-5215 September 2002 Dyslipidaemia (SMQ)
C1869037 A12057160 L6511794 S7585607 SDUI 20000034 SMQ_SOURCE Bankowski Z, Bruppacher R, Crusius I et al. Reporting adverse drug reactions, definition of terms and criteria for their use. Council for International Organizations of Medical Sciences (CIOMS), 1999 p 32 Peripheral neuropathy (SMQ)
C1869041 A12056806 L6511720 S7585411 SDUI 20000038 SMQ_SOURCE Dorland's Illustrated Medical Dictionary, Saunders, Philadelphia, 2000 Haemorrhages (SMQ)
C1869043 A12057346 L6511583 S7585435 SDUI 20000041 SMQ_SOURCE 1. Oki JC and Isley WL. Diabetes mellitus. Pharmacotherapy: A Pathophysiologic Approach (5th Ed). DiPiro JT, Talbert RL, Yee GC et al (Eds). McGraw-Hill: New York, 2002. pg. 1335-1358. 2. Powers AC. Diabetes mellitus. Harrison's Principles of Internal Medicine (15th Ed). Braunwald E, Fauci AS, Kasper DL et al (Eds). McGraw-Hill: New York, 2001. pg. 2109-2137. 3. Vanrenterghem YFC. Which calcerineurin inhibitor is preferred in renal transplantation: tacrolimus or cyclosporine? Curr Opin Nephrol Hypertension 1999; 8(6):669-674. 4. Fraenkel PG, Rutkove SB, Matheson JK et al. Induction of myasthenia gravis, myositis, and insulin-dependent diabetes mellitus by high-dose interleukin-2 in a patient with renal cell cancer. J Immunother 2002; 25(4):373-378. 5. Costa J. Corticotrophins and corticosteroids. Meyler's Side Effects of Drugs (14th Ed). Dukes MNG (Ed). Elsevier:Amsterdam, 2000. pg. 1364-1395. 6. Coates P. Miscellaneous hormones. . Meyler's Side Effects of Drugs (14th Ed). Dukes MNG (Ed). Elsevier:Amsterdam, 2000. pg. 1520-1526. 7. Heck AM, Yanovski LA, and Calis KA. Pituitary gland disorders. Pharmacotherapy: A Pathophysiologic Approach (5th Ed). DiPiro JT, Talbert RL, Yee GC et al (Eds). McGraw-Hill: New York, 2002. pg. 1395-1411. 8. Currier J. Management of metabolic complications of therapy. AIDS 2002; 16(Suppl 4):S171-S176. 9. Fantry LE. Protease inhibitor-associated diabetes mellitus: a potential cause of morbidity and mortality. JAIDS 2003; 32: 243-244. 10. Henderson DC. Atypical antipsychotic-induced diabetes mellitus. CNS Drugs 2002; 16(2):77-89. 11. Citrome LL. The increase in risk of diabetes mellitus from exposure to second-generation antipsychotic agents. Drugs of Today 2004; 40(5):445-464. 12. Melkersson K and Dahl M-L. Adverse metabolic effe Hyperglycaemia/new onset diabetes mellitus (SMQ)
C1869044 A12057523 L6511722 S7585477 SDUI 20000042 SMQ_SOURCE Not provided Interstitial lung disease (SMQ)
C1869045 A12057162 L6511592 S7585485 SDUI 20000043 SMQ_SOURCE Harrison's Textbook of Internal Medicine Ischaemic heart disease (SMQ)
C1869046 A12057701 L6511894 S7585566 SDUI 20000044 SMQ_SOURCE 1) Levenson JL. Neuroleptic malignant syndrome. Amer J Psychiatry 1985; 142(10):1137-1145. 2) Caroff SN and Mann SC. Neuroleptic malignant syndrome. Medical Clinics of North America 1993; 77(1):185-202. 3) Neuroleptic malignant syndrome. Diagnostic and Statistical Manual of Mental Disorders (4th Ed). American Psychiatric Association: Washington DC, 1994, pg. 739-742. 4) Velamoor VR. Neuroleptic malignant syndrome: recognition, prevention and management. Drug Safety 1998; 19(1):73-82. 5) Neuroleptic malignant syndrome. Reporting Adverse Drug Reactions: Definitions of Terms and Criteria for Their Use. Bankowski Z, Bruppacher R, Crusius I et al (Eds). Council for International Organizations of Medical Sciences: Geneva, 1999, pg. 31-32. 6) Simpson GM, Pi EH, and Sramek JJ. Neuroleptic and antipsychotic drugs. Meyler's Side Effects of Drugs (14th Ed). Dukes MNG and Aronson JK (Eds). Elsevier: New York, 2000, pg. 139-163. 7) Crismon ML and Dorson PG. Schizophrenia. Pharmacotherapy: A Pathophysiologic Approach (5th Ed). DiPiro JT, Talbert RL, Yee GC et al (Eds). McGraw-Hill: New York, 2002, pg. 1219-1242. 8) Hasan S and Buckley P. Novel antipsychotics and the neuroleptic malignant syndrome: a review and critique. Amer J Psychiatry 1998; 155(8):1113-1116. 9) Caroff SN, Mann SC, and Campbell EC. Atypical antipsychotics and neuroleptic malignant syndrome. Psychiatric Annals 2000; 30(5):314-321. 10) Ananth J, Parameswaran S, and Gunatilake S et al. Neuroleptic malignant syndrome and atypical antipsychotic drugs. J Clin Psychiatry 2004; 65(4):464-470. Neuroleptic malignant syndrome (SMQ)
C1869047 A12056625 L6511688 S7585723 SDUI 20000045 SMQ_SOURCE 1. Guidelines for referral and management of systemic lupus erythematosus in adults. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Guidelines. Arthritis Rheum 1999;42:1785-96. 2. Hellman DB, Stone JH. Arthritis and musculoskeletal disorders. In: Tierney, Jr. LM, McPhee SJ, Papadakis MA, editors. Current medical diagnosis and treatment. 43rd ed. New York: McGraw-Hill Companies, Inc.; 2004. Available via intranet at STAT!Ref Online Medical Database. Teton Data Systems, Jackson, Wyo. (Version 3.3.6, 2004). 3. Hahn BH. Disorders of the immune system, connective tissues, and joints. In: Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, editors. Harrison's principles of internal medicine. 16th ed. New York: McGraw-Hill Companies; 2005. Available via intranet at STAT!Ref Online Medical Database. Teton Data Systems, Jackson, Wyo. (Version 3.3.6, 2004). 4. Diffuse connective tissue disease. In: Beers MH, Berkow R, editors. The merck manual of diagnosis and therapy. 11th ed. Whitehouse Station: Merck Research Laboratories; 1999. Available via intranet at STAT!Ref Online Medical Database. Teton Data Systems, Jackson, Wyo. (Version 3.3.6, 2004). 5. Trethewey P. Systemic Lupus Erythematosus. Dimens Crit Care Nurs 2004;23:111-5. 6. CIOMS Publication, "Reporting Adverse Drug Reactions: Definitions of Terms and Criteria for their Use", pp 19 - 20, 1999. 7. The Merck Manual, Seventeenth Edition, pp 426 - 430, 1999 8. "Harrison's Principles of Internal Medicine", 14th edition, pp 1874 - 1880, 1998 9. Stratton MA Drug-induced systemic lupus erethemetosis. Clin Pharm 1985: 4:567-63 10. Yung R, Chang S, Hemati N et al. Mechanisms of drug-induced lupus. IV. Comparison of procainamide and hydralazine with analogs in vitro and Systemic lupus erythematosus (SMQ)
C1869048 A12057163 L6511854 S7585728 SDUI 20000046 SMQ_SOURCE 1. The Merck Manual, 17th ed., 1999, p 687 2. Harrison's Principles of Internal Medicine, 14th ed., 1998, pp 173 - 175 3. Doty, RL et al. Influences of antihypertensive and antihyperlipidemic drugs on the senses of taste and smell: a review. J Hypertens21: 1805 -1813 4. Stedman's Medical Dictionary, 27th ed., 2000. Taste and smell disorders (SMQ)
C1869051 A12057164 L6511628 S7585238 SDUI 20000049 SMQ_SOURCE 1. Bankowski Z, Bruppacher R, Crusius I et al. Reporting adverse drug reactions, definition of terms and criteria for their use. Council for International Organizations of Medical Sciences (CIOMS), 1999. Page 78. 2. Harrison's Principles of Internal Medicine 16th ed, Mc Graw Hill, 2005, pp 1333-58. Cardiac arrhythmias (SMQ)
C1869058 A12057872 L6511566 S7585252 SDUI 20000060 SMQ_SOURCE The Merck Manual (Seventeenth Edition), 1999 Cerebrovascular disorders (SMQ)
C1869060 A12057703 L6511830 S7585484 SDUI 20000063 SMQ_SOURCE The Merck Manual (Seventeenth Edition), 1999 Ischaemic cerebrovascular conditions (SMQ)
C1869062 A12057349 L6511487 S7585664 SDUI 20000065 SMQ_SOURCE 1. CIOMS, Reporting Adverse Drug Reactions, 1999, p 20-21. 2. Khan, AN. Retroperitoneal fibrosis. 13 September 2002. http://www.emedicine.com/radio/topic605.htm. 3. Diamond, JR. Clinical manifestations and diagnosis of retroperitoneal fibrosis. UpToDate(r), 27 February 2005 http://www.utdol.com/ Retroperitoneal fibrosis (SMQ)
C1869063 A12056987 L6511611 S7585685 SDUI 20000066 SMQ_SOURCE 1. Harrison's Principles of Internal Medicine 16th ed, Mc Graw Hill, 2005, pp 1581, 1600-1605 2. Dorland's Illustrated Medical Dictionary, 28th ed, Philadelphia WB Saunders Co. 3. Reporting Adverse Drug Reactions, Definitions and Criteria for Their Use, CIOMS, Geneva, 1999 4. Harrison's Principles of Internal Medicine 16th ed, Mc Graw Hill, 2005, pp 1367-71 Shock (SMQ)
C1869064 A12057734 L6511848 S7585686 SDUI 20000067 SMQ_SOURCE 1. Harrison's Principles of Internal Medicine 16th ed, Mc Graw Hill, 2005, pp 1581, 1600-1605 2. Dorland's Illustrated Medical Dictionary, 28th ed, Philadelphia WB Saunders Co. 3. Reporting Adverse Drug Reactions, Definitions and Criteria for Their Use, CIOMS, Geneva, 1999 4. Harrison's Principles of Internal Medicine 16th ed, Mc Graw Hill, 2005, pp 1367-71 Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (SMQ)

SOS

  (return to top)
CUI METAUI LUI SUI STYPE CODE ATN ATV STR
C1869006 A12057156 L6511616 S7585752 SDUI 20000001 SOS 1. Includes sudden and cardiac death terms as this is a frequent association with torsade de pointes. Torsade de pointes/QT prolongation (SMQ)
C1869007 A12057867 L6511681 S7585665 SDUI 20000002 SOS 1. Renal impairment/failure terms included because of the frequent association with rhabdomyolysis Rhabdomyolysis/myopathy (SMQ)
C1869091 A12057875 L6511505 S7585241 SDUI 20000004 SOS The CIOMS Working Group discussed in detail whether an algorithm could be applied to this SMQ based on the definition of cardiac failure provided. Such an algorithm, however, has not been tested by the CIOMS Working Group, therefore, the Working Group is requesting users to comment on the practical relevance of an algorithm approach. Such an algorithm could involve broad tersmsas follows: one oedema term, one dyspnoea term plus one clinical/sign/symptom or investigation making up 3 terms in total Cardiac failure (SMQ)
C1869038 A12057161 L6511588 S7585462 SDUI 20000021 SOS The following algorithm is used: All narrow search terms as well as: If one term from category B and one term from category C is present, or If one term from (category B or category C) plus one term from category D. Anaphylactic reaction (SMQ)
C1869025 A12057005 L6511764 S7585273 SDUI 20000022 SOS To apply algorithm - A report is considered a relevant case for further review if: 1) it includes a term from Category A (Narrow terms) OR 2) it includes at least one term from Category B (the list of laboratory values) and at least one term from Category C (the list of signs and symptoms) Acute pancreatitis (SMQ)
C1869026 A12056983 L6511876 S7585355 SDUI 20000023 SOS If possible, full blood counts and repeated white blood cell counts should be reported, sought for in follow up, and coded. Concerning database queries with broad search terms, additionally coded data on hematological values help to find relevant cases more easily. In case laboratory values are not coded in a database, individual review is then needed to decide upon relevance in the context of agranulocytosis. Agranulocytosis (SMQ)
C1869035 A12057345 L6511725 S7585492 SDUI 20000032 SOS At the present time, this SMQ is most appropriate to drugs; blood components/derivatives; and cellular, tissue, and gene therapy products. It is less appropriate to vaccine products, which seem better suited to the specialized searches described in this document. This SMQ is not appropriate to devices. This SMQ can be modfied by the user for specific product types and classes. Please see the SMQ Introductory Guide for details. Lack of efficacy/effect (SMQ)
C1869036 A12057159 L6511663 S7585493 SDUI 20000033 SOS Testing in two regulatory databases confirmed that the term list is adequate; in one regulatory database, the term "acidosis" identified cases, but this may be a phenomenon of the database characteristics (coding of verbatims to terms of an older terminology or other coding conventions). Lactic acidosis (SMQ)
C1869039 A12057871 L6511451 S7585311 SDUI 20000035 SOS PTs Intentional overdose and Poisoning deliberate were included in both the Depression search and the Suicide/self-injury search since they include LLTs suggestive of suicide or self-injury. However, inclusion of these PTs (particularly PT Intentional overdose) substantially increased the number of cases identified by both the depression and suicide/self-injury searches in phase I testing. It was the practice of the testing company to encode any case where the patient was prescribed a dose that exceeded the maximum-labeled daily dose as an intentional overdose, regardless of whether or not an overdose was being reported. Therefore, many of these cases do not involve true "overdoses". For databases where this is a common practice, it would not be unreasonable to conduct an initial search excluding these two PTs. For databases where this is not a common practice, these two PTs should be included routinely in both searches. Depression and suicide/self-injury (SMQ)
C1869041 A12056806 L6511720 S7585411 SDUI 20000038 SOS PT Blood urine was included although it could be interpreted as a lab test only without stating explicitly that blood was present in urine. However, this term is usually used in order to describe the finding of blood in urine. Note: Coders should have chosen PT Blood urine present if the intent was to code blood being present in the urine (macroscopically even without test). Haemorrhages (SMQ)
C1869043 A12057346 L6511583 S7585435 SDUI 20000041 SOS In phase I testing (company database), some broad search terms PTs (Blood cholesterol increased, Blood triglycerides increased, Weight decreased, and Weight increased) retrieved considerable "noise", but this may be dependent on the drugs selected for testing. The CIOMS WG has concluded that these PTs need to be included for completeness sake, and if the narrow search identifies a sufficient number of cases for a review then cases reporting only these PTs may not need to be reviewed further. However, should the narrow search return an insufficient number of cases for review, then cases reporting these PTs should be reviewed to determine if the patient in those cases appear to be at high risk for subsequent development of diabetes mellitus or hyperglycemia. Testing in the regulatory database similarly retrieved "noise" for PT Weight increased; however, the CIOMS WG development team agreed that this term is relevant for the scope of the SMQ and should remain in the query for now. MedDRA users are asked to specifically focus on this term during phase II testing and provide feedback on its overall utility for this SMQ Hyperglycaemia/new onset diabetes mellitus (SMQ)
C1869046 A12057701 L6511894 S7585566 SDUI 20000044 SOS Algorithm : Category A: specific reports of NMS or the similar conditions serotonin syndrome or malignant hyperthermia; Category B (fever-related PTs); Category C (muscle rigidity or injury-related PTs); Category D (other relevant NMS-related PTs) Cases to be selected for further review would include any cases reporting at least one of the PTs listed for Category A or any case reporting some combination of at least one PT from each of the three groups of PTs listed as Categories B, C and D. Neuroleptic malignant syndrome (SMQ)
C1869047 A12056625 L6511688 S7585723 SDUI 20000045 SOS Use of weighted algorithm in this SMQ: 1. The PTs mentioned in the case report are grouped according to the pre-determined categories. Occurrence of multiple PTs within a category is counted only once 2. The category that the term is attributed to is then multiplied by its empirically pre-determined "weight" (for example - 3 for categories Haematologic disorder, Serositis, and Immunologic disorder) and summed for all the categories 3. If this sum is greater than 6, it is proposed that the case report qualifies as a suspected SLE case report. For example, a case report which has PTs in the categories of Hematologic disorder (3), Immunologic disorder (3) and Renal disorder (1) will classify as a SLE broad search case report (3 + 3 + 1 = 7) Systemic lupus erythematosus (SMQ)
C1869048 A12057163 L6511854 S7585728 SDUI 20000046 SOS In phase I testing, cases in a company test database describing unpleasant taste and smell of the medical substance were also coded using the same terms (e.g., PT Dysgeusia). Medical review is required to distinguish between reports of the medical disorder and the physical properties of the treatment compound Taste and smell disorders (SMQ)
C1869050 A12057347 L6511537 S7585552 SDUI 20000048 SOS Category A (Narrow): Cases encoding to PT Anticholinergic syndrome Categories B, C and D (Broad): Category B (Nervous system-related PTs) Category C (Psychiatric-related PTs) Category D (Other relevant anticholinergic syndrome-related PTs) Cases to be selected for further review would include any cases reporting the PT listed for Category A or any case reporting some combination of at least one PT from each of the three groups of PTs listed as Categories B, C and D. Note: cases may not include a description that includes terms from more than one SOC. If it is considered important to identify these cases then a non-algorithmic approach should be taken for the broad search; however, this approach may identify a large number of irrelevant cases. Anticholinergic syndrome (SMQ)
C1869051 A12057164 L6511628 S7585238 SDUI 20000049 SOS For phase II testing, subscribers are asked to test the SMQ Cardiac arrhythmias and its sub-searches with the exception of the sub-search SMQ Torsade de pointes/QT prolongation which has previously been circulated for phase II testing and is currently in production. Cardiac arrhythmias (SMQ)
C1869062 A12057349 L6511487 S7585664 SDUI 20000065 SOS The narrow search was able to retrieve the majority of relevant cases. The addition of PT Abdominal pain to the broad search retrieved many additional cases which would not have been retrieved by the narrow search. Thus, both PT Abdominal pain and PT Abdominal pain lower are included in this query. Retroperitoneal fibrosis (SMQ)
C1869076 A12056631 L6511904 S7585645 SDUI 20000080 SOS The terms Diarrhoea and Diarrhoea haemorrhagic should be included in the narrow search if the compound is an antibiotic; they should remain in the broad search if the compound is not an antibiotic. PT Clostridial infection includes LLTs for non-specific "clostridial" descriptions, as well as non-C. difficile species; cases identified via PT Clostridial infection should be carefully reviewed for relevance. Pseudomembranous colitis (SMQ)
C1869077 A12057528 L6511822 S7585332 SDUI 20000081 SOS In order to get all relevant terms of embolism and thrombosis, it may be necessary to combine the sub-searches of this SMQ. SMQ Cerebrovascular accidents, SMQ Vasculitis and SMQ Thrombophlebitis should also be taken into consideration. Embolic and thrombotic events (SMQ)

MISO

  (return to top)
CUI METAUI LUI SUI STYPE CODE ATN ATV STR
C0851353 A1585002 L1372278 S1626383 SDUI 10005329 MISO 03 Blood and lymphatic system disorders
C0018799 A1588768 L0537218 S1629626 SDUI 10007541 MISO 11 Cardiac disorders
C0851352 A2016522 L1376503 S2162599 SDUI 10010331 MISO 21 Congenital, familial and genetic disorders
C0851354 A1595679 L1378038 S1635566 SDUI 10013993 MISO 10 Ear and labyrinth disorders
C0014130 A1595701 L0161501 S1635589 SDUI 10014698 MISO 05 Endocrine disorders
C0015397 A1595746 L0012705 S1635657 SDUI 10015919 MISO 09 Eye disorders
C0017178 A1595807 L0161543 S1635716 SDUI 10017947 MISO 14 Gastrointestinal disorders
C0851362 A1577054 L1368040 S1619777 SDUI 10018065 MISO 22 General disorders and administration site conditions
C0267792 A2017358 L1853427 S2163231 SDUI 10019805 MISO 15 Hepatobiliary disorders
C0021053 A1595893 L0161607 S1635802 SDUI 10021428 MISO 04 Immune system disorders
C0009450 A1603505 L1381725 S1642343 SDUI 10021881 MISO 01 Infections and infestations
C0947733 A2017507 L1853110 S2163342 SDUI 10022117 MISO 24 Injury, poisoning and procedural complications
C1261322 A0976668 L0861064 S0919672 SDUI 10022891 MISO 23 Investigations
C0851358 A1595997 L1378196 S1635896 SDUI 10027433 MISO 06 Metabolism and nutrition disorders
C0263660 A2018017 L1194718 S2163723 SDUI 10028395 MISO 17 Musculoskeletal and connective tissue disorders
C0027651 A2018135 L1852696 S2163814 SDUI 10029104 MISO 02 Neoplasms benign, malignant and unspecified (incl cysts and polyps)
C0027765 A1596081 L0297185 S1635977 SDUI 10029205 MISO 08 Nervous system disorders
C0851363 A1592150 L1376383 S1632589 SDUI 10036585 MISO 19 Pregnancy, puerperium and perinatal conditions
C0004936 A1596183 L0297219 S1636064 SDUI 10037175 MISO 07 Psychiatric disorders